Prediction: This Is Where Pfizer Stock Will Be in 2030

Pfizer faces significant patent expirations for major drugs (Ibrance, Xtandi, and Eliquis) between 2027-2028, which is pressuring its stock valuation and causing investor concern. However, the company is expected to recover by 2030 through new drug development and acquisitions, with management predicting high-single-digit revenue growth post-2028. While the company maintains an attractive 6.4% dividend yield, ongoing patent cliff risks remain a structural challenge for the business.

08/22/2026, 10:15 AM • The Motley Fool

Protalix (PLX) Q2 2026 Earnings Call Transcript

Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.

08/19/2026, 10:08 AM • The Motley Fool

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Bristol-Myers Squibb are compared as dividend-paying pharmaceutical investments. AbbVie shows stronger revenue growth (8.6% YoY) driven by Skyrizi and Rinvoq, while Bristol-Myers Squibb faces patent cliff headwinds despite trading at a significant valuation discount. The article recommends AbbVie for long-term investors due to its focused operations, accelerating neuroscience portfolio, and attractive dividend, despite Bristol-Myers Squibb's recovery potential.

08/14/2026, 3:26 PM • The Motley Fool

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

08/14/2026, 10:30 AM • The Motley Fool

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.

08/11/2026, 4:27 PM • The Motley Fool

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.

08/07/2026, 3:28 PM • The Motley Fool

Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence

ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

08/07/2026, 5:56 AM • GlobeNewswire

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.

08/07/2026, 5:54 AM • GlobeNewswire

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer appears undervalued with a 6.8% dividend yield and low P/E ratio of 8.5x, but investors remain skeptical due to negative revenue growth over three years and upcoming patent cliffs, particularly for its blockbuster drug Eliquis. However, the company's deep pipeline in weight management and oncology, including promising candidates like MET-097i and PF-4404, could drive significant recovery if clinical trials succeed, making it potentially attractive for long-term income investors.

07/31/2026, 3:09 PM • The Motley Fool

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

07/26/2026, 7:30 PM • GlobeNewswire

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.

Pfizer's 6.8% dividend yield significantly exceeds market averages, raising concerns about sustainability. However, management remains committed to maintaining and growing the dividend, as evidenced by Q1 2026 earnings presentations. The company generated sufficient operating cash flow to cover dividend payments and maintain a higher cash balance, supported by $11.3 billion in long-term investments. While Pfizer faces industry headwinds including patent expirations and delays in GLP-1 drug development, analysts suggest the company has the financial capacity to sustain its dividend through this challenging period.

07/25/2026, 8:15 AM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.

07/20/2026, 3:15 AM • The Motley Fool

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer's stock has fallen over 50% from late 2021 highs, pushing its dividend yield to a historically high 6.9%. While the company faces normal industry headwinds including upcoming patent expirations and disappointing new drug development, management remains committed to protecting the dividend. The company is taking steps to address challenges, including acquiring a weight-loss drug candidate after dropping its own GLP-1 drug. More aggressive dividend investors may find Pfizer's valuation compelling despite risks.

07/19/2026, 7:15 AM • The Motley Fool